Grace Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Grace Therapeutics, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $26 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
26%Of every $100 the company owns, $26 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 95% of Healthcare companies in United States.
Tangible Net Worth Ratio
23%Of every $100 of net worth, $23 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 65% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Grace Therapeutics, Inc. made a loss over the last year. Grace Therapeutics, Inc. owes $0.04 for every $1 it owns. Grace Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Mar 2026.
P/E ratio
LossGrace Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.84The share price is 0.84 times Grace Therapeutics, Inc.'s book value per share, lower than 83% of Healthcare companies in United States.
Market cap
$40 MThe total market value of all of Grace Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 76% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$48 MWhat Grace Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.29Net worth divided by the number of shares. The share price of $1.91 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-36.2%Grace Therapeutics, Inc. lost 36.2% of its shareholders' money over the last year, higher than 58% of Healthcare companies in United States.
Owes vs Owns
0.04×Grace Therapeutics, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Dividend yield
NoneGrace Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossGrace Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Grace Therapeutics, Inc.: $40 M ÷ $48 M (30 Jun 2026) = 0.8.
What is Grace Therapeutics, Inc.'s return on equity?
Grace Therapeutics, Inc. lost 36.2% of its shareholders' money over the last year, higher than 58% of Healthcare companies in United States.
How much does Grace Therapeutics, Inc. owe compared with what it owns?
Grace Therapeutics, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Does Grace Therapeutics, Inc. pay a dividend?
No. Grace Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.